Presentation Executive English Revised

8/14/2019 Presentation Executive English Revised

1/33

Executive Presentation

Mass vaccination using MIT CANADA Needle-Free Jet InjectorMED-JET H-III


2/33

2

Presentation Objectives

Presenting MIT CANADA and its founder

Demonstrate the integral factors in the useof the Med-Jet needle-free jet injector

Outlining the inherent advantages in theuse of the Med-Jet needle-free jet injector

Conclusion of the presentation


3/33

3

History of MIT Canada and itsfounder

Our goal is to develop a needle-free drug

delivery system using state-of-the-arttechnology for the Human and

Veterinary medicine communities and

make the world needle-free.
http://www.epictura.com/product_info.php?products_id=1465783http://www.epictura.com/product_info.php?products_id=1465783http://www.epictura.com/product_info.php?products_id=1465783http://www.epictura.com/product_info.php?products_id=1465783http://www.epictura.com/product_info.php?products_id=1465783http://www.epictura.com/product_info.php?products_id=1465783http://www.epictura.com/product_info.php?products_id=1465783http://www.epictura.com/product_info.php?products_id=1465783


4/33

4

MIT Canada founderKarim Menassa

Born in Cairo, Egypt, in 1951. In 1968, he received his diploma

as a designer in precisionmechanics.

Immigrated to Canada in 1970and received his immigrationstatus in 1976.

Designed the first needle-free jetinjector for human application in

1978 and continued to improve ituntil 1984. Has over 30 years of experience

in research, development, anddesign of medical equipments

and devices.


5/33

5

MIT Canada: itspast,its presentand its future

Founding of the company Ide International R&D Inc in 1984 Filing the patent for its needle-free injector for diabetics during the

first year. Research and development of its first needle-free jet injector for animal

applications; signed a multi-million dollar agreement with US company

Pitman & Moore (over $5 million was spent to adapt the injector to thecompanys need) Pitman & Moore invested well over 50 million$ to adapt their hormones to the

Lene-Jet of Idee. The venture aborted in 1993 when Pitman & Moore could not obtain the

approval from FDA and thereafter was acquired by Mallinckrodt Pharmaceutical.

The animal project was revived in 1997. In 2000, the new needle-

free injector was conceived with new technological advancementsand was given the current name of Agro-Jet, which includes manymodels.

Founding of MIT Canada in 1998 and operations started in 2002.

More than 20 million spent in R & D since 1984


6/33

6

MIT Canada: its past, itspresentand its future

Publicly traded corporation in development

Traded at the Nasdaq stock Exchange (OTCBB - MDLH) 5,000 ft2 of offices and an option of additional 2,500 ft2

An estimated market value from 2002 between $48 and$56 Million dollars evaluated by Wise & Blackman

Employs 6 people and has 6 subcontractors/suppliers in

Quebec Has the capacity to produce 100 units per month at 95 % Quebec components Applied for a $350,000 PPE loan for the purchasing of 4

injection molding machines 49% Shareholder of a Canadian/Chinese joint venture,

located in Jiangsu Province, Taizhou, declared by theCentral Government to be China Medical City with8,000 ft2 of operation facilities granted by the localChinese Government. (see pictures on left)

The only company in the world that can offer Needle-Free injectors for mass inoculations with volume

and pressure adjustment suited for the vaccinationof Humans and Animals


7/33

7

MIT Canada: its past, itspresent (2)and its future

Honouring a-5 year contract ($6 Million) to supply itsMalaysian Distributor with Med-Jet MBX The Med-Jet MBX is sold in Asia for US$ 8,000

Distributes its human models in 15 countries aroundthe world including Canada

Distributes its animal models in 33 countries aroundthe world including Canada More than 1,200 AGRO-JET in use since 2001

Negociating with 2 multinational pharmaceuticalcompanies for exclusive right in the animal market

In discussion with a major pharmaceutical companyfor exclusive right in the human dentistry market

Investes annually between $250,000 to $400,000 inR&D

Many certifications: Health Canada certification, European Union certification ISO certification

Sales of over $600 000 this year


8/33

8

MIT Canada: its past, its presentand its future

Growing public companyProjected: Will eventually be listed on the AMEX or

the NASDAQ. Will have modern manufacturing facilities

in Quebec, USA, Europe, China andMexico.

Will employ more than 100 people inQuebec alone.

Will be able to manufacture more than5,000 injectors per month.

To obtain certification from FDA. To become the world leaderof a global

market estimated at over 4 billion$ peryear.


9/33

9

Motivations underlying the use of aneedle-free injector

There are multiple


10/33

10

What is the history behind theneedle-free injector?

By 1866, there already were writings on this subjectand even images of injectors.

In 1934, the first real needle-free injectors wereconceived in the hope of better control of epidemicsin Europe and to vaccinate soldiers. The Russians were pioneers in this area Unfortunately, those injectors were very inefficient,

costly and too heavy

The 1970s saw renewed interest in this technologybecause of technological advances in: Composite materials Drugs with smaller molecular structures

In 1997, under the auspices of the World HealthOrganization, ANFIM (Association of Needle-FreeInjection Manufacturers) was founded. MIT CANADA will join this association when FDA

approval will be obtained
http://www.epictura.com/product_info.php?products_id=1076736


11/33

11

Why is its use not widespreadtoday?

Because:

Technology, despite all the efforts that weremade, was not yet fully developed in the past Using too much pressure lead to persistent pain No possibility of intradermal injection

Nobody has really produced a detailed analysisof costs and benefits associated with its use

Nothing is really possible without the support ofnational and global institutions

Manufacturers of needle-free injectors, invery small numbers around the world, have little

or no capacity for lobbying and marketing The multinational pharmaceutical

companies had no interest The health professionals do not yet know the

technology Citizens have yet to experience the comfort of

vaccination with such injectors
http://www.epictura.com/product_info.php?products_id=1165480http://www.epictura.com/product_info.php?products_id=1183937


12/33

12

What modivating factors could helpspread its use?

The resurgence of infectious and very contagious viruses affectingthe world

A H1N1, H5N1, SARS, mad cow disease, etc.

The stronger will of global organizations to eradicate certainendemic diseases (eg: malaria)

3,3 billion people at risk; 247 million cases of malaria in 2007 causing one milliondeaths

The threat of proliferation of biological weapons by terrorist nationsand organizations

The expressed wishes to help Africa and other countries in theThird World:

The One Foundation, Oprah, Bill Clinton, Bill Gates In 2007, the G8 pledged 60 billion to help Africa

The desire to reduce accidents related to the use of syringes withneedles

The desire to reduce the side effects of drug absorption The desire to make the planet greener (Recycling) Brazil returns 1,400 tons of used syringes to Great Britain

Compassion for humanity, its suffuring and fears, rational or not Medical science tries again and again to reduce or control pain at its lowest level

We now realize that everything is connected, the infected animalmay, in turn, contaminate humans


13/33

13

The main motivation:contamination

Contamination is the medical term used todescribe the invasion of a living organism bypathogenic micro-organisms

Preventive measures always have their place Hygiene (washing hands, wearing a mask, wash

the infected areas, etc.) More extreme measures also become necessary

The slaughter of animals The isolation or containment of population in

restricted zones Mass vaccination then takes on all its meaning

(Better safe than sorry) It should begin at the animal as it may, living or

dead, be the main factor for disease transmission Mass vaccination must be supervised by public

health departments


14/33

14

Possible consequences ofcontamination

Any threat of contamination, if not treatedpromptly, can lead to: Important loss of animal and human life Indescribable Human suffering Staggering costs of hospitalization Incalculable financial losses

Of course, we must first have developed avaccine and have produced it in largevolumes 95 % of actual drugs can now be

administered using needle-free injector Everything depends on the viscosity of

the injection solution

Thereafter, it is essential to have themeans to administer the vaccine quicklyand on a large scale


15/33

15

Another motivation:Reduce accidents with syringes

We already know that a factor of thespreading of AIDS (0,3%) and hepatitis Bet C (10 %) comes from the use ofcontaminated needles

But is it also known that: 800 000 accidents with needles have been

listed in the U.S. alone in 1999 Approximately 35 50 % of these cases

affects health workers

The prevalence rate of accidents is

estimated at nearly 5 per 100 000injections

On average, each case results in directand indirect costs of over US $2,500


16/33

16

Further motivation: Elimination ofFear and Pain

Many people simply hate getting vaccinated It is estimated that nearly 10 % of the population has a significant fear

of needles

This fear leads to the following: Some simply do not get vaccinated and do not go to the dentist The time required to vaccinate frightened people may waste time and

therefore money Others, such as diabetics will deliberately skip doses making

treatment less effective

The MIT Needle-Free Injector is painless

The diameter of the jet (gauge) is 10 times smaller (270) than theneedle used to vaccinate (27) The smallest needle in the world has a gauge of 33

Blood tests could be done without any pain or discomfortto the patient if a tiny injection of 0.03ml of localanesthesia is administered using the MED-JET MBX priorto entering the needle.

MIT CANADA has the only needle-free injector in the worldthat can inject such a small volume (0.02 0.3 ml)
http://www.epictura.com/product_info.php?products_id=126891http://www.epictura.com/product_info.php?products_id=1466931http://www.epictura.com/product_info.php?products_id=736733


17/33

17

Why choose the needle-freeinjector today?

The technology is ready and available


18/33

18

Injection accuracyandeffectiveness

Vaccination of a drug, an antibiotic, Botox, etc. mustbe done in one of the following 4 approaches: Intradermal (into the skin between the epidermis and

dermis) The most difficult to do For tuberculosis, spa treatments

Subcutaneous (under the skin in the dermis) Eg: For diabetics

Intramuscular (must always check that it has not hit avein)

Quite painful

Intravenous The most painful and uncomfortable

A needle-free injector can be used in the first 3 typesof vaccination. Only MIT CANADA MED-JET H-III model is designed for all

three 3 types of injection in one

Intradermal vaccination (possibly the most effectivefor absorption of medication) becomes easy with theMED-JET MBX


19/33

19

Injection accuracy andeffectiveness

The effectiveness of injection should take intoconsideration the following 3 elements: The injection site

The depth of injection In reference to the type of vaccination

The period of drug absorption This last factor is not really taken into account althought it is

probably the most important

The difference between an injection syringue andan injection with the needle-free injector is night andday for the last 2 criteria With the pressure regulator associated with the

needle-free injector, we control the depth of injection

By using a spray, the injected substance is absorbedmore quickly in the body

In doing so, less medication is required and takes effect morequickly


20/33

Th (2) MED JET d l f


21/33

21

The (2) MED-JET models forhuman: Principal advantages

Does not produce waste

Increase drug absoprtion(Less medication required)

More opportunities in thesiting of vaccination

ccuracy of injection and reliability

ays difficult to achieve using a needle)

Less damage to tissueand less pain

Increased efficiency forintradermal vaccination

Fast (At least 3 times morevaccine per hour)

Th AGRO JET f i l


22/33

22

The AGRO-JET for animal(11 different models)

Principal features: Between 600 and 3 000 injections per hour Adjustable & accurate dose (0.1 5cc) Light weight between 0.7 Kg to 1.5 Kg Accurary of 99 % 1cc Reliable and durable

Their main advantages: The same as human models There is evidence that the use of needles

causes stress to animals, which affectstheir growth

It should be noted that a version of the AGRO-JETwas tested for over 2 years by Pitman & Moore who

called it powerful and very reliable

P ibl li ti f
http://www.epictura.com/product_info.php?products_id=1389891http://www.epictura.com/product_info.php?products_id=1462162http://www.epictura.com/product_info.php?products_id=1498939http://www.epictura.com/product_info.php?products_id=1461564http://www.epictura.com/product_info.php?products_id=1203673


23/33

23

Possible applications forneedle-free injector

There are many

U f dl f i j t


24/33

24

Use of needle-free injectorfor human

The syringe (with needle) in humans isused for a multitude of applications: The injection of vaccines, hormones, Botox,

insulin, lidocaine, etc. Blood tests Intravenous

Approximately 50 to 55% of thesecould be done by a needle-freeinjector because they dont need topierce a vein The worldwide annual consumption of syringes is

estimated at more 12 billion units

Use of needle free injector
http://www.epictura.com/product_info.php?products_id=536653


25/33

25

Use of needle-free injectorfor human (2)

Other applications :

Hair transplant

Palmar and plantar hyperhidrosis (with Botox)

Treatment of migraine (with Botox)

Injection of collagen

Liposuction

Local anesthesia

A vast majority of medical interventionsinvolving the use of a syringe with needle

Use of needle free injector


26/33

26

Use of needle-free injectorfor animal

The syringe (with needle) in animals is mainly used for: The injection of vaccines

The injection of antibiotics

The injection of hormones

Blood tests

The use of syringes with needles could therefore beabandoned in more than95 % of situations

The same needle is used to vaccinate at least 25 andoften more than 100 animals, which can lead to:

Risk of contamination

Abscesses

Risk of accidents

Fragments of left needle into the body of the animal


27/33

27

Advantages of needle-free injector

They are astonishing

Advantages of needle free


28/33

28

Advantages of needle-freeinjector for human

The needle-free injector can:

Eliminate a significant number of accidents caused by the use ofneedles

Significantly reduce the doses of vaccines currently used Tests would be desirable although MIT CANADA is satisfied that the report

findings would be similar to those obtained from tests done in the animal sector

Reduce stress and pain in humans

Reduce the side effects of drugs injected

Ensure safe injections in each individual

Lessening skin problems in diabetics who need to vaccinate everyday

Advantages of needle free


29/33

29

Advantages of needle-freeinjector for animal

The needle-free injector can:

Eliminate the accidents leaving needles inanimals These animals must pass through a metal

detector in order to locate the fragment

Substantially reduce the doses of druginjection Tests done by MIT CANADA with the company

Schering-Plough Animal Health showed that thedose of vaccine could be reduced by 5 to 10times maintaining the same efficiency

Eliminate abscesses caused by needles Eliminate the stress and pain of the animal Ensure equal injections in each animal

Only 0.2 % of the animals in the worldare vaccinated using a needle-free

injector
http://www.imageforum-diffusion.afp.com/ImfDiffusion/themes/displayTheme.aspx?ThemeID=2402220


30/33

30

A Cost/Benefits analysis

The Quebec government buys 1,750 MED-JET H-III for 6million injections Costs: 10 million Benefits: 55 million

Less vaccine used Less effort to vaccinate (1/3 less)

Other non-financial benefits A reduction of economic loss due to absenteeism at work

162 million days of work are lost annually in Canada due to the common cold

Greater coverage

People are less afraid to come get vaccinated A government initiative very well received by the population A government initiative very well received by health workers


31/33

31

MIT CANADA future projects

Obtain FDA approval to open up U.S. market Botox Cosmetic awaits only FDA approval

to begin advertisement campains for the useof MIT CANADAs needle-free injector amongits users around the world

The needle-free injector for dentists (2010)

The needle-free injector for diabetics (2010) World Health Organization (WHO) estimates that there will

be 300 million diabetics worldwide in 2025 There were already 194 million in 2003 (China alone

accounts for over 80 million)

And why not a needle-free injector for each doctor and dentist
http://www.epictura.com/product_info.php?products_id=1071633http://www.epictura.com/product_info.php?products_id=1071632http://www.epictura.com/product_info.php?products_id=1077774


32/33

32

Conclusion

The technology is available,

reliable and economical

The leader of thistechnology is Canadian

Eliminating needles in human and animalmarkets makes a world of sense


33/33

33

Are you ready ?

Lets roll up our sleeves

For a safer world

Presentation Executive English Revised

Documents

Transcript of Presentation Executive English Revised